Effects of Growth Hormone and Dehydroepiandrosterone on Women with Poor Ovarian Reserve During In Vitro Fertilization

What this Trial Is About

Researchers are evaluating the effects of Somatropin and Dehydroepiandrosterone DHEA on ovarian reserve and the outcome of intracytoplasmic sperm injection ICSI in women who respond poorly to ovarian stimulation. This study aims to determine which treatment is more effective at increasing the number and size of follicles, which are important for successful fertilization and pregnancy in infertility treatment. The trial is conducted by Beni-Suef University and includes women aged 18 to 35 years with poor ovarian response. Participants are randomly assigned to one of three groups one receiving Somatropin injections of 4 IU every 3 days for at least 1 month along with daily folic acid another receiving DHEA 50 mg twice daily for 12 weeks plus daily folic acid and a control group receiving standard care with folic acid only. The treatment periods vary, with Somatropin given for about 1 month and DHEA for 12 weeks, followed by an ICSI cycle to assess treatment effects. During the study, participants are followed for 12 weeks while undergoing their assigned treatments and the ICSI procedure. Researchers will measure the number of mature eggs collected after treatment and monitor pregnancy rates as secondary outcomes. These assessments help determine how well each intervention supports ovarian function and fertility. The total study duration includes the treatment period and follow-up through the assisted reproduction cycle.

Growth Hormone and Dehydroepiandrosterone Role in Vitro Fertilization